Brief: BiomX Provides A Program Update And Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
17/10/2025 13:32
Oct 17 (Reuters) - Biomx Inc PHGE.A: BIOMX PROVIDES A PROGRAM UPDATE AND ANNOUNCES NEW FDA FEEDBACK POTENTIALLY EXPANDING BX004 DEVELOPMENT PATHWAYS BIOMX INC - PHASE 2B RESULTS EXPECTED Q1 2026 BIOMX INC - ADDRESSES FDA QUERIES ON NEBULIZER FOR BX004 BIOMX INC - FDA RECOGNIZES UNMET NEED FOR CF THERAPIES BIOMX INC: FDA HAS NOT RAISED ANY CONCERN REGARDING BX004 DRUG PRODUCT Source text: ID:nGNX7kYtzJ Further company coverage: PHGE.A
Recent news on Biomx
See all newsBrief: Biomx Inc - Buys 100% Of Zorronet From Water Io - SEC Filing
Brief: BiomX Obtains Option To Acquire Control Of Israeli Laser-Radar Counter-Drone System
Brief: Biomx Adds Former Mossad Deputy To Advisory Board
Brief: Biomx Inc - Jonathan Solomon Resigns As CEO And Board Member Effective March 4, 2026 - SEC Filing
Brief: BiomX Says Unaware of Any Undisclosed Developments Amid Unusual Stock Trading